As discussed in this publication by Professor Jennifer Rogers last week, there have been discrepancies in the data reported by AstraZeneca in its trial of the coronavirus vaccine. Professor Rogers noted in particular:
We are told that one dosing regimen (with a sample size of 2,741 participants) showed efficacy of 90 per cent when the ChAdOx1 nCOV19 vaccine was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (with a sample size of 8,895) showed 62 per cent efficacy when given as two full doses at least one month apart. The
Already a subscriber? Log in
Get 10 issues
for $10
Subscribe to The Spectator Australia today for the next 10 magazine issues, plus full online access, for just $10.
- Delivery of the weekly magazine
- Unlimited access to spectator.com.au and app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in